Patient and caregiver involvement in the formulation of guideline questions: findings from the European Academy of Neurology guideline on palliative care of people with severe multiple sclerosis.


Journal

European journal of neurology
ISSN: 1468-1331
Titre abrégé: Eur J Neurol
Pays: England
ID NLM: 9506311

Informations de publication

Date de publication:
01 2019
Historique:
received: 26 02 2018
accepted: 16 07 2018
pubmed: 24 7 2018
medline: 4 6 2019
entrez: 24 7 2018
Statut: ppublish

Résumé

Patient and public involvement in clinical practice guideline development is recommended to increase guideline trustworthiness and relevance. The aim was to engage multiple sclerosis (MS) patients and caregivers in the definition of the key questions to be answered in the European Academy of Neurology guideline on palliative care of people with severe MS. A mixed methods approach was used: an international online survey launched by the national MS societies of eight countries, after pilot testing/debriefing on 20 MS patients and 18 caregivers, focus group meetings of Italian and German MS patients and caregivers. Of 1199 participants, 951 (79%) completed the whole online survey and 934 from seven countries were analysed: 751 (80%) were MS patients (74% women, mean age 46.1) and 183 (20%) were caregivers (36% spouses/partners, 72% women, mean age 47.4). Participants agreed/strongly agreed on inclusion of the nine pre-specified topics (from 89% for 'advance care planning' to 98% for 'multidisciplinary rehabilitation'), and <5% replied 'I prefer not to answer' to any topic. There were 569 free comments: 182 (32%) on the pre-specified topics, 227 (40%) on additional topics (16 guideline-pertinent) and 160 (28%) on outcomes. Five focus group meetings (three of MS patients, two of caregivers, and overall 35 participants) corroborated the survey findings. In addition, they allowed an explanation of the guideline production process and the exploration of patient-important outcomes and of taxing issues. Multiple sclerosis patient and caregiver involvement was resource and time intensive, but rewarding. It was the key for the formulation of the 10 guideline questions and for the identification of patient-important outcomes.

Sections du résumé

BACKGROUND AND PURPOSE
Patient and public involvement in clinical practice guideline development is recommended to increase guideline trustworthiness and relevance. The aim was to engage multiple sclerosis (MS) patients and caregivers in the definition of the key questions to be answered in the European Academy of Neurology guideline on palliative care of people with severe MS.
METHODS
A mixed methods approach was used: an international online survey launched by the national MS societies of eight countries, after pilot testing/debriefing on 20 MS patients and 18 caregivers, focus group meetings of Italian and German MS patients and caregivers.
RESULTS
Of 1199 participants, 951 (79%) completed the whole online survey and 934 from seven countries were analysed: 751 (80%) were MS patients (74% women, mean age 46.1) and 183 (20%) were caregivers (36% spouses/partners, 72% women, mean age 47.4). Participants agreed/strongly agreed on inclusion of the nine pre-specified topics (from 89% for 'advance care planning' to 98% for 'multidisciplinary rehabilitation'), and <5% replied 'I prefer not to answer' to any topic. There were 569 free comments: 182 (32%) on the pre-specified topics, 227 (40%) on additional topics (16 guideline-pertinent) and 160 (28%) on outcomes. Five focus group meetings (three of MS patients, two of caregivers, and overall 35 participants) corroborated the survey findings. In addition, they allowed an explanation of the guideline production process and the exploration of patient-important outcomes and of taxing issues.
CONCLUSIONS
Multiple sclerosis patient and caregiver involvement was resource and time intensive, but rewarding. It was the key for the formulation of the 10 guideline questions and for the identification of patient-important outcomes.

Identifiants

pubmed: 30035845
doi: 10.1111/ene.13760
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

41-50

Commentaires et corrections

Type : ErratumIn

Informations de copyright

© 2018 EAN.

Auteurs

S Köpke (S)

Institute of Social Medicine and Epidemiology, University of Lübeck, Lübeck, Germany.

A Giordano (A)

Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

S Veronese (S)

FARO Charitable Foundation, Turin, Italy.

A Christin Rahn (A)

Institut für Neuroimmunologie und Multiple Sklerose (INIMS), Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.

I Kleiter (I)

Kempfenhausen Centre for Treatment of Multiple Sclerosis, Marianne-Strauß-Klinik, Berg, Germany.

B Basedow-Rajwich (B)

Kempfenhausen Centre for Treatment of Multiple Sclerosis, Marianne-Strauß-Klinik, Berg, Germany.

A Fornari (A)

Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

M A Battaglia (MA)

Department of Life Sciences, University of Siena, Siena, Italy.

J Drulovic (J)

Clinic of Neurology, CSS, Faculty of Medicine, University Hospital of Belgrade, Belgrade, Serbia.

L Kooij (L)

Nieuw Unicum, Zandvoort, The Netherlands.

J Koops (J)

Nieuw Unicum, Zandvoort, The Netherlands.

J Mens (J)

Nieuw Unicum, Zandvoort, The Netherlands.

E R Meza Murillo (ER)

MS Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.

I Milanov (I)

Neurology Clinic, Medical University of Sofia, Sofia, Bulgaria.

R Milo (R)

Department of Neurology, Barzilai Medical Center, Ashkelon, Israel.
Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel.

F Patti (F)

Neurology Clinic, Multiple Sclerosis Centre, University Hospital Policlinico Vittorio Emanuele, Catania, Italy.

T Pekmezovic (T)

Institute of Epidemiology, Faculty of Medicine, University of Belgrade, Belgrade, Serbia.

J Sastre-Garriga (J)

MS Centre of Catalonia (Cemcat), University Hospital Vall d'Hebron, Barcelona, Spain.

J Vosburgh (J)

Israel Multiple Sclerosis Society, Tel-Aviv, Israel.

R Voltz (R)

Department of Palliative Medicine, University Hospital Cologne, Cologne, Germany.

J Bay (J)

Multiple Sclerosis International Federation, People with MS Advisory Committee, Copenhagen, Denmark.

D J Oliver (DJ)

The Tizard Centre, University of Kent, Canterbury, UK.

A Solari (A)

Unit of Neuroepidemiology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH